By Hu Yangxiaoxiao 胡阳潇潇
The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay
近日，A&O Shearman作为BioNTech的法律顾问，为其收购中国生物医药公司普米斯提供法律服务；高赢国际律师事务所则为普米斯提供法律意见。
BioNTech将以8亿美元预付款收购普米斯100%已发行股本，支付方式主要为现金和部分美国存托股份（ADS）；此外，BioNTech将在普米斯达到双方约定的里程碑条件时，额外支付最高1.5亿美元的里程碑付款。
该交易预计于2025年第一季度完成。BioNTech未来将支持普米斯的肿瘤研究计划，并获得普米斯研发的BNT327药物的全球所有权——此前，普米斯拥有该药物在大中华地区的商业化权利，并已在癌症患者身上展开临床试验。
普米斯2018年成立于珠海，未来普米斯珠海将成为BioNTech中国研发中心开展相关R&D研究。
A&O Shearman团队由合伙人Matthew Appleton和Clare O'Brien牵头，中国知识产权业务合伙人葛轶君提供支持。
高赢团队由其纽约/香港合伙人潘文森率领。
*欢迎点击阅读原文，登录ALB官方网站浏览更多法律资讯！
A&O Shearman, Goodwin on China’s biotech firm’s $950 mln M&A deal
A&O Shearman has advised German drugmaker BioNTech on its $950 million proposed acquisition of China biotech startup Biotheus, with Goodwin Procter advising the acquiree in the deal.
Under the terms of the agreement, BioNTech will pay 800 million dollars for 100% of the issued share capital, with additional milestone payments of up to 150 million dollars.
The transaction is expected to close in the first quarter of 2025. BioNTech will support Biotheus’ oncology strategy and gain full global rights to its bispecific antibody candidate BNT327, which has been tested in clinical trials with tumor patients. Biotheus previously held the right to commercialize it in the Greater China market.
Moving forward, Biotheus' Zhuhai facility will serve as BioNTech's China R&D centre.
The A&O Shearman team was led by partners Matthew Appleton, Clare O'Brien, with assistance from China IP partner Jill Ge.
The Goodwin team was led by Wendy Pan, and Mayan Katz.
欢迎您随时将律所最新资讯推送给ALB，请将资讯发至：
ALBChinaEditor@thomsonreuters.com，并注明您的姓名、律所名称及联系方式。
